RedHill Biopharma Ltd. (RDHL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

RedHill Biopharma Ltd. (RDHL) Healthcare & Pipeline Overview

RedHill Biopharma Ltd. (RDHL) specializes in developing innovative therapies for gastrointestinal conditions and infections, leveraging a strong late-stage clinical pipeline and a portfolio of marketed products to address critical healthcare needs.

What Is the Investment Thesis for RDHL?

The company has several key products already on the market, including Movantik, Talicia, and Aemcolo, which address significant healthcare needs and contribute to its revenue stream. The ongoing development of investigational drugs such as RHB-204 and Opaganib could further enhance its market position, particularly as these therapies target high-prevalence conditions with limited treatment options. With a market cap of $2.05M and a gross margin of 63.3%, RedHill is strategically positioned to leverage its innovative pipeline for future growth. However, the company faces challenges such as a high profit margin of -98.7%, necessitating careful monitoring of clinical trial outcomes and regulatory approvals to achieve profitability. Investors should evaluate the potential of RedHill’s products and pipeline to drive future revenue growth, alongside the inherent risks associated with the pharmaceutical industry.

Based on FMP financials and quantitative analysis

RDHL Key Highlights

Market cap of $2.05M, indicating a focus on growth rather than profitability at this stage.

• Gross margin of 63.3%, showcasing the potential for high profitability once operational efficiencies are achieved.
• Profit margin of -98.7%, reflecting the company's current investment phase in R&D and clinical trials.
• Beta of 4.97, indicating high volatility and potential risk for investors.
• No dividend yield, as the company is reinvesting earnings into its product pipeline.

Who Are RDHL's Competitors?

RDHL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are RDHL's Key Strengths?

Specialized focus on gastrointestinal diseases, a niche with high unmet needs.

• Strong pipeline of investigational drugs with potential for high returns.
• Established products that generate revenue and market presence.
• Expertise in clinical trials and regulatory approval processes.

What Are RDHL's Weaknesses?

High operating loss reflected in a profit margin of -98.7%.

• Limited market cap of $2.05M, indicating potential funding challenges.
• Dependence on a few key products for revenue generation.
• Small employee base of 35, which may limit operational capacity.

What Could Drive RDHL Stock Higher?

RDHL catalyst: RHB-204 is expected to enter the market in 2027 if Phase 3 trials are successful, addressing a significant patient population.

• Opaganib's Phase 2 trials for COVID-19 pneumonia are currently underway, with results anticipated in the coming months.
• RHB-104's Phase 3 trials for Crohn's disease are progressing, with potential regulatory submissions planned for 2026.
• RHB-102 (Bekinda) is in Phase 3 trials for acute gastroenteritis, with results expected later this year.
• RHB-106 is preparing to commence Phase 2/3 clinical studies, which could broaden RedHill's product portfolio.

What Are the Key Risks for RDHL?

Financial-distress signal — its Altman Z-Score of -24.08 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles may delay the approval of investigational drugs, impacting the company's growth trajectory.
• High volatility in the stock price, indicated by a beta of 4.97, poses risks for investors.
• Dependence on a limited number of products for revenue generation could expose RedHill to market fluctuations.
• Clinical trial failures could result in significant financial losses and hinder future product development.

What Are the Growth Opportunities for RDHL?

• Growth opportunity 1: RedHill Biopharma's RHB-204 is currently in Phase 3 trials for pulmonary nontuberculous mycobacteria infections, a condition that affects approximately 10,000 patients annually in the U.S. alone. If successful, this product could tap into a market valued at over $1 billion, with potential launch expected in 2027, presenting a significant revenue opportunity.
• Growth opportunity 2: Opaganib (Yeliva) has shown promise in treating severe COVID-19 pneumonia and is currently in Phase 2 trials. The global market for COVID-19 treatments is projected to reach $50 billion by 2027, and if Opaganib receives regulatory approval, it could capture a substantial share of this market, further enhancing RedHill's growth trajectory.
• Growth opportunity 3: The increasing prevalence of Crohn's disease presents a significant opportunity for RedHill's RHB-104, which is in Phase 3 development. With an estimated 780,000 patients in the U.S. suffering from this condition, the market for Crohn's disease treatments is projected to exceed $7 billion by 2026, positioning RedHill to benefit from this growing demand.
• Growth opportunity 4: The company's RHB-102 (Bekinda) is progressing through Phase 3 trials for acute gastroenteritis and gastritis, targeting a market that is expected to grow significantly due to rising incidences of gastrointestinal infections. Successful commercialization could lead to substantial revenue growth, particularly as awareness of digestive health continues to rise.
• Growth opportunity 5: RedHill's RHB-106, an encapsulated formulation for bowel preparation, is preparing to commence Phase 2/3 clinical studies. The bowel preparation market is expected to grow significantly, driven by increasing screening rates for colorectal cancer. If RHB-106 proves effective, it could capture a meaningful share of this market, further diversifying RedHill's product offerings.

What Opportunities Does RDHL Have?

• Growing market for gastrointestinal treatments with increasing patient demand.
• Potential for successful drug approvals that could drive revenue growth.
• Strategic partnerships to enhance research and market reach.
• Expansion into new therapeutic areas beyond gastrointestinal diseases.

What Threats Does RDHL Face?

• Regulatory hurdles that could delay product approvals.
• Intense competition from larger pharmaceutical companies.
• Risks associated with clinical trial failures or adverse outcomes.
• Market volatility impacting funding and investment opportunities.

What Are RDHL's Competitive Advantages?

• Strong focus on niche therapeutic areas with limited competition.
• Robust pipeline of investigational drugs addressing unmet medical needs.
• Established products with proven efficacy and market acceptance.
• Expertise in navigating regulatory processes for drug approvals.
• Strategic partnerships that enhance research capabilities and market access.

What Does RDHL Do?

Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill Biopharma Ltd. is a specialized pharmaceutical company dedicated to developing and commercializing proprietary drugs primarily targeting gastrointestinal diseases and infections. The firm has built a reputation for focusing on unmet medical needs, particularly in the area of digestive tract conditions. RedHill markets several key products, including Movantik, which treats opioid-induced constipation in adults with chronic non-cancer pain; Talicia, for Helicobacter pylori infections; and Aemcolo, aimed at adults suffering from travelers' diarrhea. The company boasts a promising late-stage clinical pipeline, featuring investigational compounds such as RHB-204, currently in Phase 3 trials for pulmonary nontuberculous mycobacteria infections, and Opaganib (Yeliva), which has completed Phase 2 for severe COVID-19 pneumonia and is also being studied for advanced unresectable cholangiocarcinoma and prostate cancer. Additionally, RHB-107 is advancing through Phase 2/3 trials for COVID-19 outpatients, while RHB-104 is in Phase 3 development for Crohn's disease. The company’s commitment to innovation and development is evident in its robust pipeline, which includes RHB-102 (Bekinda) for acute gastroenteritis and gastritis, and RHB-106, an encapsulated formulation for bowel preparation, set to begin Phase 2/3 studies. RedHill Biopharma continues to position itself as a key player in the pharmaceutical sector, focusing on high-demand therapeutic areas with significant growth potential.

What Products and Services Does RDHL Offer?

• Develops proprietary drugs targeting gastrointestinal diseases and infections.
• Markets several approved medications for digestive tract conditions.
• Conducts late-stage clinical trials for investigational compounds.
• Focuses on addressing unmet medical needs in the pharmaceutical sector.
• Engages in research and development to innovate new therapies.
• Operates primarily in the U.S. and Israel markets.

How Does RDHL Make Money?

• Generates revenue through the sale of approved pharmaceutical products.
• Invests heavily in research and development to bring new drugs to market.
• Licenses its proprietary drugs to other pharmaceutical companies.
• Pursues partnerships and collaborations to enhance product development.
• Engages in clinical trials to validate the efficacy of its investigational drugs.

What Industry Does RDHL Operate In?

The pharmaceutical industry, particularly within the specialty and generic drug manufacturing sector, is experiencing significant growth driven by increasing demand for innovative therapies and an aging population. The global market for gastrointestinal drugs is projected to expand as awareness of digestive health increases and the prevalence of related disorders rises. RedHill Biopharma operates within this dynamic landscape, focusing on niche areas that are often underserved by larger pharmaceutical companies. The competitive landscape includes both established players and emerging biotech firms, each vying for market share in a rapidly evolving industry. RedHill's specialized focus on gastrointestinal diseases positions it well to capitalize on these trends and address unmet medical needs.

Who Are RDHL's Key Customers?

• Healthcare providers and hospitals that prescribe gastrointestinal medications.
• Pharmacies that distribute RedHill's pharmaceutical products.
• Patients suffering from gastrointestinal diseases and infections.
• Research institutions involved in clinical trials and drug development.
• Pharmaceutical partners interested in licensing RedHill's products.

Over the past six months, RedHill Biopharma Ltd. insiders filed 4 SEC Form 4 transactions — 2 sales and 2 purchases. On net that is roughly 29.1M shares acquired (about $3K) — insiders putting money in tends to read as conviction.

Wall Street analysts project RedHill Biopharma Ltd. revenue of about $50.6M for fiscal 2026, with EPS near $0.00.

RedHill Biopharma Ltd. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 976.0% above estimates on average.

RedHill Biopharma Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.08 places it in the distress zone, a signal of elevated financial risk.

Return on equity for RedHill Biopharma Ltd. stands at 291.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.5%, showing how much profit it generates from its asset base. A current ratio of 0.34 means current liabilities exceed short-term assets, a liquidity point worth watching.

RedHill Biopharma Ltd. (RDHL) Valuation Context

Valued at $2.05M, RDHL is classified as a micro-cap stock. Relative to its peer group, RDHL's quantitative score of 19/100 is below the peer average of 55/100.

RDHL Revenue & Earnings Trend

In Q2 FY2025, RDHL generated $2.0M in top-line revenue, marking a sequential increase of 0.0%. The company recorded a net loss of $2.1M, with diluted EPS of $-1.15. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, RDHL averaged $-1.08 in diluted EPS.

Company Profile

RedHill Biopharma Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tel Aviv, IL. The company is led by CEO Dror Ben-Asher. RDHL has traded publicly since 2013.

RDHL Financials

RDHL Latest News

RDHL Analyst Consensus

RDHL MoonshotScore

RDHL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources